Open AccessCirculating levels of IL‐11 and leukaemia inhibitory factor (LIF) do not significantly participate in the production of acute‐phase proteins by the liver
Author(s) -
GABAY C.,
SINGWE M.,
GENIN B.,
MEYER O.,
MENTHA G.,
LE COULTRE C.,
VISCHER T.,
GUERNE P.A.
Publication year - 1996
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1046/j.1365-2249.1996.d01-757.x
Subject(s) - acute phase protein , haptoglobin , rheumatoid arthritis , immunology , in vivo , medicine , fibrinogen , cytokine , inflammation , biology , microbiology and biotechnology
To investigate the contribution of IL‐11 and LIF to acute‐phase protein (APP) production, we first analysed the effects of IL‐11 and LIF on production of C‐reactive protein (CRP), fibrinogen, and haptoglobin by human primary hepatocytes. We also measured the serum levels of IL‐11, LIF, and CRP in serum from patients with inflammatory rheumatic diseases to assess the role of these cytokines in the APP response in vivo . We included patients with conditions associated with a high APP response such as rheumatoid arthritis (RA) or spondylarthropathy (SpA), and others usually associated with a weak APP response such as systemic lupus erythematosus (SLE), in order to investigate whether these cytokines could account for the differences in APP responses. Our results showed that IL‐11 and LIF induced only minimal stimulation on production of APP by human primary hepatocytes compared with IL‐6, known as the major inducer. Serum levels of CRP were elevated in RA and SpA, and significantly higher than in SLE patients. Despite the presence of a high APP response in some of our patients and despite the fact that we used sensitive assays to measure IL‐11 and LIF, serum levels of both cytokines were not detected in any of the tested sera. In conclusion, our results show that circulating levels of IL‐11 or LIF do not contribute significantly to the production of APP in vivo , and that they do not account for the difference in APP response between SLE and other inflammatory rheumatic diseases.